[REVISION HISTORY]
Global antimicrobial and fungal resistance challenges
39 recorded revisions of this situation.
What changed
2026-11-19 07:47 UTC → 2026-11-19 15:55 UTC ·
added
removed
Global health experts continue to warn of the ‘silent pandemic’ of antimicrobial resistance (AMR), which is currently responsible for approximately one million deaths annually. To address this, Member States approved a 10-year Global Action Plan in May 2026, targeting a 10 per cent reduction in the crisis through the ‘One Health’ approach. This approach recognizes that human health is linked to animal and environmental health, addressing factors like antibiotic overuse, sanitation, and farming practices. During World Antimicrobial Awareness Week in November 2026, the WHO reported that while 173 countries have developed national plans, significant gaps in funding, testing, and treatment persist. According to the 2026 TrACSS survey, which included 183 countries, the number of nations with AMR plans has more than doubled since 2017, yet only 22 per cent of countries reported having the necessary funding to fully implement these plans. Diagnostic capacity remains a critical weakness, as only 36 per cent of countries possess national reference laboratories equipped to test selected bacteria and fungi. In the Western Pacific, WHO Representative Erin Kenney warned that approximately 5.2 million people could die from drug-resistant bacteria between 2020 and 2030. In Vietnam, experts noted that improper use, such as self-medicating for viral infections, accelerates resistance, with A. baumannii showing a 63 per cent resistance rate. Economically, the WHO forecasts that by 2035, the cost of treating resistant infections could reach 412 billion USD annually. In Europe, the ECDC has warned that the region is falling behind its 2030 targets. Despite a 5 per cent reduction in While antibiotic consumption in the EU decreased by 5 per cent between 2019 and 2025, bloodstream infections caused by carbapenem-resistant Klebsiella pneumoniae rose by 72 per cent. Additionally, In the Netherlands, the incidence of these infections rose by 450 per cent during the same period. E. coli resistance to third-generation cephalosporins has increased by 16.4 per cent across the EU, with Spain seeing a 76.1 per cent rise. In Greece, the Hellenic Infectious Diseases Society reported that AMR is an immediate threat in both hospitals and the community. Greece has approximately four times the incidence of carbapenem-resistant Klebsiella pneumoniae bacteremia compared to the EU average, and its third-generation cephalosporin-resistant E. coli bacteremia has increased by 109 per cent since 2019. Furthermore, Greece maintains one of the highest antibiotic consumption rates in the EU, at 29.9 defined daily doses per 1,000 inhabitants.
Versions
- 2026-11-19 15:55 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-19 07:47 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-19 04:17 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-18 20:33 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-18 18:33 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-18 12:27 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-18 12:13 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-18 10:46 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-18 08:30 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-18 08:24 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-18 06:44 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-18 05:32 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-18 05:31 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-17 17:33 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-17 10:43 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-17 04:25 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-16 21:12 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-16 19:01 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-16 13:30 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-16 12:17 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-16 12:03 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-16 09:46 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-16 08:54 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-15 12:41 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-11 22:31 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-10 08:23 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-08 18:38 UTC Global antimicrobial and fungal resistance challenges
- 2026-11-07 08:25 UTC Global antimicrobial and fungal resistance challenges
- 2026-10-30 16:31 UTC Global antimicrobial and fungal resistance challenges
- 2026-10-30 13:04 UTC Global antimicrobial and fungal resistance challenges
- 2026-10-29 03:27 UTC Global antimicrobial and fungal resistance challenges
- 2026-10-28 23:24 UTC Global antimicrobial and fungal resistance challenges
- 2026-10-21 12:57 UTC Global antimicrobial and fungal resistance challenges
- 2026-10-17 10:33 UTC Global antimicrobial resistance challenges
- 2026-10-15 07:58 UTC Global antimicrobial resistance challenges
- 2026-10-13 05:51 UTC Global antimicrobial resistance challenges
- 2026-10-04 10:08 UTC Global antimicrobial resistance challenges
- 2026-10-03 18:56 UTC Global antimicrobial resistance challenges
- 2026-09-29 08:35 UTC Global antimicrobial resistance challenges
- 2026-09-25 06:42 UTC Global antimicrobial resistance challenges
Select a version to see what changed compared to the one before it.